Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. - Wikidata - wikimedia - TriplyDB

Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin.

Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin.

http://www.wikidata.org/entity/Q38403090

about

Neuroplasticity and the next wave of antidepressant strategies Erythropoietin enhances hippocampal long-term potentiation and memory Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials Erythropoietin in Friedreich ataxia Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons Erythropoietin prevents haloperidol treatment-induced neuronal apoptosis through regulation of BDNF The hematopoietic cytokine granulocyte-macrophage colony stimulating factor is important for cognitive functions.Systematic review of the neural basis of social cognition in patients with mood disorders.Expression of constitutively active erythropoietin receptor in pyramidal neurons of cortex and hippocampus boosts higher cognitive functions in mice Research in people with psychosis risk syndrome: a review of the current evidence and future directions Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.Revisiting adult neurogenesis and the role of erythropoietin for neuronal and oligodendroglial differentiation in the hippocampus Erythropoietin improves operant conditioning and stability of cognitive performance in mice.Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways Erythropoietin ameliorates early ischemia-reperfusion injury following the Pringle maneuver.Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling.Hemoglobin concentration and cognitive impairment in the renal REasons for Geographic And Racial Differences in Stroke (REGARDS) Study.A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation.Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?Nitric oxide synthase mediates the ability of darbepoetin alpha to improve the cognitive performance of STOP null mice Influence of erythropoietin on cognitive performance during experimental hypoglycemia in patients with type 1 diabetes mellitus: a randomized cross-over trial Survival and proliferative roles of erythropoietin beyond the erythroid lineage.Levels of S100B are raised in female patients with schizophrenia.The management of cognitive impairment in bipolar disorder: current status and perspectives.Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke.Activating mitochondrial function and haemoglobin expression with EH-201, an inducer of erythropoietin in neuronal cells, reverses memory impairment Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia.Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol.Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies Methods for treating cognitive deficits in schizophrenia.Molecular mechanisms of schizophrenia.Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia.Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system.Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial.Effects of recombinant human erythropoietin in normal humans.Intranasal erythropoietin therapy in nervous system disorders.Emerging drugs for schizophrenia.Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression.

P2860

Q21129480-3D666FD2-4E65-43F7-B733-C1FD529EFAF4 Q21245342-8E7FDCA4-A859-4912-B338-43A4F1C35FF8 Q26741541-DF0795B4-88F7-4299-B22C-0693D0546580 Q26863216-E6B6809D-907A-4E54-8C72-9DC33AE91D08 Q28570180-E8E29829-EACB-42F3-8745-DBD8B2880380 Q28580029-9F0EBE77-D59E-4A74-9120-60CF0898066C Q30463376-22DFC283-D3C0-4CFE-95E7-956A35DB679D Q30467590-C913356F-1B03-42E0-B9F8-05DE50E1F368 Q30475059-39E02DBB-2F12-4E2F-8A98-B884A37A209E Q30475598-59C567E2-BB59-4F0B-8C48-0C6D882E9052 Q30483012-A4ECF2F1-26CA-4203-9B69-C7491E3755B1 Q30833366-42F7C29A-D922-4962-B95C-505B490AF33B Q33479749-10A777BC-5A4A-4C1F-9C28-AFD4E89074EF Q33762512-42A0A3E2-BD04-4465-99C6-BCC4A3C0FFB8 Q34200868-9ABCC9DB-61EF-4523-A2CE-2FA6645785CB Q34258204-2AC2CEE0-D8F0-43D9-84E7-F2A624B48D21 Q34274859-78B78A0F-57E0-4000-A96E-16A32DA044AC Q34304678-A81D73A0-283F-41B4-9752-C450C364BACA Q34342726-7D503BBD-7F75-45B1-8516-DFAE3094B27A Q34405264-3380C7E9-9B7F-48FC-B359-A172A65D970B Q34504572-E2BC913A-062F-48DF-9EA3-6351CFC0B040 Q34661087-1E4F093B-1339-4073-9D77-820EC46BF0EB Q34663582-D18B8E63-6B37-46F2-9D60-40AB95ECDB78 Q34725972-D150334D-D59D-42B8-A96F-C967C4FF92AB Q34738782-ABB91A17-BB2E-4CCD-B999-533E2D726DA8 Q35582604-1A2AC6AC-F16B-4AC1-A5E9-0B86E6FB9080 Q36066188-B1A2FD6A-1F6E-4210-8EBA-DCD30F20134C Q36124238-0ED76601-201D-406F-88A7-93C2536C5E4E Q36283435-C39028CD-2AAD-43FA-A26A-9F8761F5499E Q36670604-9E3FD0A6-AF53-413B-8DB4-A244E39EA67E Q36740470-47577D95-FE0A-4FD7-B61A-B43BD87F80AB Q36752922-DB03410B-0F2E-4199-A6A0-82AE204288BA Q36992703-0436365C-D41E-4683-BAF2-3C0610FE2DA8 Q37078047-C8EA72E0-3DF7-43E1-8A69-2B2E892AD772 Q37358669-F416E76C-0523-451A-B617-7FCADF46F813 Q37705741-10AF8C28-3B5E-49C2-A60A-921238530763 Q37784333-16D7F2AF-5C0B-4B59-8507-4C84C4FA6479 Q37818329-F9220E4D-75B2-400C-9F99-52F486FC92D0 Q37874626-3FE0011E-219D-497C-A85D-F57B505B35AE Q37938732-34F66AAF-88BC-4779-A3AD-E7D3521E73E6

P2860

Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin.

http://www.wikidata.org/entity/Q38403090

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Improvement of cognitive funct ...... ombinant human erythropoietin.

@en

type

label

Improvement of cognitive funct ...... ombinant human erythropoietin.

@en

prefLabel

Improvement of cognitive funct ...... ombinant human erythropoietin.

@en

P1433

Q38403090-BD5635E0-3189-4C53-A953-E1220BFC116C

P1476

Q38403090-EA4D4766-EE24-4544-9BAB-2941574782E8

P2093

Q38403090-0403EDD7-55B2-4743-91D4-38F5CCA29474

Q38403090-159A31B7-7CC7-4427-BD96-998860A3DD94

Q38403090-19470535-2498-4DE0-8563-2D72C396F036

Q38403090-22242498-3E4D-450D-8E25-07E15337084C

Q38403090-37BFFBDF-E5F6-4754-A395-4318A134EDA0

Q38403090-396F2816-5EE9-4245-A255-4DF1A0A9EFC4

Q38403090-3BDF4F2A-D6F2-4CAC-9363-CE4794BC3C46

Q38403090-61189AC3-B2D2-4EA4-A2A5-03F17427EFBD

Q38403090-73EFE6B8-43FB-4065-B57A-225B1E438156

Q38403090-75B3EE53-B7B3-4225-9E33-FFF87BB82199

P2860

Q38403090-030A5F35-7E24-42E9-A8FE-F0B9DBB381CE

Q38403090-05891C7C-3F65-41D0-9E8B-7441FA233F07

Q38403090-08921A15-F876-4335-BACD-0179C5C467E4

Q38403090-0C2B89EA-F5DC-44E1-BF30-D1B28B59A4FB

Q38403090-0E7884F4-F9ED-48A2-BC73-42D5C60E3D19

Q38403090-0F3424A7-2895-4C91-BEBC-0724384F8E2D

Q38403090-126BB468-348B-42FF-8279-A86BAA9B0048

Q38403090-21BB4AD3-CC8C-4057-BE78-8544C56CDE9D

Q38403090-28DC7858-B825-425C-A686-2EC30D43E890

Q38403090-315D952C-5041-4176-9464-71B44E943DBF

P2888

Q38403090-7B2C7ACC-A09B-436E-9E32-8DABC96F08D7

P304

Q38403090-21271FA0-A5FE-443D-9421-F8774E12FD88

P31

Q38403090-D63DEB46-7567-43C7-981C-E1FD6184BDD1

P356

Q38403090-4E4100C7-EA32-4BF7-BC59-2E997D8979A6

P407

Q38403090-FA983AD0-AC2C-44BF-BCE9-2BCD2316FFB6

P433

Q38403090-D94BA8C7-811E-499B-8357-79B452718BF6

P478

Q38403090-00793A13-2961-4CC0-8541-DC745A939CBC

P50

Q38403090-723D8990-4709-4A31-BE79-60082FED4CC6

P577

Q38403090-BDEAFA44-7523-4315-AAC6-F24309B0ECCE

P5875

Q38403090-96D9BC3A-B29E-452B-B598-83AA4BF2967B

P6179

Q38403090-3B931363-E80C-4ED4-8E63-78F85C997474

P698

Q38403090-F011D182-C6AB-4DB5-BBAB-121AACF49A48

P921

Q38403090-C2E9BF7A-954C-423A-9732-264987F9AC2F

Q38403090-D369DFBA-82BD-4C1F-865F-493347D8D8FC

P356

P1433

Molecular Psychiatry

P1476

Improvement of cognitive funct ...... ombinant human erythropoietin.

@en

P2093

Aldenhoff JB

http://www.w3.org/2001/XMLSchema#string

Aust C

http://www.w3.org/2001/XMLSchema#string

Bohn M

http://www.w3.org/2001/XMLSchema#string

Czernik A

http://www.w3.org/2001/XMLSchema#string

Degner D

http://www.w3.org/2001/XMLSchema#string

Ehrenreich H

http://www.w3.org/2001/XMLSchema#string

Erdag S

http://www.w3.org/2001/XMLSchema#string

Falkai P

http://www.w3.org/2001/XMLSchema#string

Heinz G

http://www.w3.org/2001/XMLSchema#string

Hinze-Selch D

http://www.w3.org/2001/XMLSchema#string

P2860

Anemia of inflammation: the cytokine-hepcidin link

Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress

Theories of schizophrenia: a genetic-inflammatory-vascular synthesis

Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress

The S100 protein family: history, function, and expression

The positive and negative syndrome scale (PANSS) for schizophrenia

Glial protein S100B modulates long-term neuronal synaptic plasticity

Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective.

Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain?

Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment.

P2888

P304

206-220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.MP.4001907

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6760956

http://www.w3.org/2001/XMLSchema#string

P6179

1008256404

http://www.w3.org/2001/XMLSchema#string

P698

17033631

http://www.w3.org/2001/XMLSchema#string

P921